{"DataElement":{"publicId":"6972656","version":"1","preferredName":"Clinical Trial Site 18F-Fluorothyminde Radiotracer Access To Manufacturing Ability Clinical Study Lead Organization Approval Received Ind","preferredDefinition":"A response used to determine whether or not a clinical trial sites access to or ability to manufacture a 18F-Fluorothymidine radiotracer has been approved by the clinical study lead organization.","longName":"6972527v1.0:3506068v1.0","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"6972527","version":"1","preferredName":"Clinical Trial Site Fluorothymidine F-18 Radioactive Label Access To Manufacture Ability Clinical Study Lead Organization Approval Receive","preferredDefinition":"Any healthcare organization, institution, facility or provider directly involved in conducting or facilitating a particular clinical trial._A radioconjugate consisting of a thymidine analogue radiolabeled with fluorine F 18, a positron emitting isotope.  Phosphorylated by S-phase-specific thymidine kinase 1, 3'-deoxy-3'-[18F]fluorothymidine (18F-FLT) is trapped intracellularly by entering the salvage pathway of DNA synthesis without incorporation into DNA. 18F-FLT serves a marker of tumor cell proliferation for imaging with positron emission tomography (PET); as a marker of proliferation rather than metabolism, it is more specific to tumor tissue than 2-deoxy-2-[18F] fluoro-D-glucose (18F-FDG).  This agent is metabolically stable, accumulates in the normal bone marrow and the liver, and does not cross the blood-brain barrier._A substance containing a radioisotope that has an affinity for and binds to a chosen biologic substance of interest to enable quantification of biologic processes._The right to obtain or make use of or take advantage of something (as services or membership); the right to enter.  Also, an act or means of approaching._Used as a function word to indicate direction, purpose, or movement._The act of making something (a product) from raw materials._The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment._An organization responsible for the overall scientific and administrative coordination, study monitoring, and data management activities of a particular clinical trial._Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval._To take, accept, or get something offered.","longName":"5044392v1.0:6972739v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"5044392","version":"1","preferredName":"Clinical Trial Site","preferredDefinition":"Any healthcare organization, institution, facility or provider directly involved in conducting or facilitating a particular clinical trial.","longName":"C85838","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Trial Site","conceptCode":"C85838","definition":"Any healthcare organization, institution, facility or provider directly involved in conducting or facilitating a particular clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"245AC863-B974-AC57-E050-BB89AD433ECE","latestVersionIndicator":"Yes","beginDate":"2015-11-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6972739","version":"1","preferredName":"Fluorothymidine F-18 Radioactive Label Access To Manufacture Ability Clinical Study Lead Organization Approval Receive","preferredDefinition":"A radioconjugate consisting of a thymidine analogue radiolabeled with fluorine F 18, a positron emitting isotope.  Phosphorylated by S-phase-specific thymidine kinase 1, 3'-deoxy-3'-[18F]fluorothymidine (18F-FLT) is trapped intracellularly by entering the salvage pathway of DNA synthesis without incorporation into DNA. 18F-FLT serves a marker of tumor cell proliferation for imaging with positron emission tomography (PET); as a marker of proliferation rather than metabolism, it is more specific to tumor tissue than 2-deoxy-2-[18F] fluoro-D-glucose (18F-FDG).  This agent is metabolically stable, accumulates in the normal bone marrow and the liver, and does not cross the blood-brain barrier.:A substance containing a radioisotope that has an affinity for and binds to a chosen biologic substance of interest to enable quantification of biologic processes.:The right to obtain or make use of or take advantage of something (as services or membership); the right to enter.  Also, an act or means of approaching.:Used as a function word to indicate direction, purpose, or movement.:The act of making something (a product) from raw materials.:The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment.:An organization responsible for the overall scientific and administrative coordination, study monitoring, and data management activities of a particular clinical trial.:Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval.:To take, accept, or get something offered.","longName":"6972739v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorothymidine F-18","conceptCode":"C49093","definition":"A radioconjugate consisting of a thymidine analogue radiolabeled with fluorine F 18, a positron emitting isotope.  Phosphorylated by S-phase-specific thymidine kinase 1, 3'-deoxy-3'-[18F]fluorothymidine (18F-FLT) is trapped intracellularly by entering the salvage pathway of DNA synthesis without incorporation into DNA. 18F-FLT serves a marker of tumor cell proliferation for imaging with positron emission tomography (PET); as a marker of proliferation rather than metabolism, it is more specific to tumor tissue than 2-deoxy-2-[18F] fluoro-D-glucose (18F-FDG).  This agent is metabolically stable, accumulates in the normal bone marrow and the liver, and does not cross the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Radioactive Label","conceptCode":"C94962","definition":"A substance containing a radioisotope that has an affinity for and binds to a chosen biologic substance of interest to enable quantification of biologic processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Access","conceptCode":"C25396","definition":"The right to obtain or make use of or take advantage of something (as services or membership); the right to enter.  Also, an act or means of approaching.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Manufacture","conceptCode":"C43360","definition":"The act of making something (a product) from raw materials.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Ability","conceptCode":"C78209","definition":"The quality of being able to perform; a quality that permits or facilitates achievement or accomplishment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Clinical Study Lead Organization","conceptCode":"C70790","definition":"An organization responsible for the overall scientific and administrative coordination, study monitoring, and data management activities of a particular clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Approval","conceptCode":"C25425","definition":"Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"945477A6-0F30-6493-E053-F662850A18B4","latestVersionIndicator":"Yes","beginDate":"2019-10-07","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-10-07","modifiedBy":"ONEDATA","dateModified":"2019-10-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435020","version":"1","preferredName":"Diagnostic, Therapeutic, and Research Equipment","preferredDefinition":"An object needed to perform a diagnostic, therapeutic or research activity.","longName":"C19238","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831F-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94540E6D-20EE-74CB-E053-F662850AE691","latestVersionIndicator":"Yes","beginDate":"2019-10-07","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-10-07","modifiedBy":"GARRIDOJ","dateModified":"2021-03-08","changeDescription":"Created for EA6183, 10/07/2019, JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Has ECOG-ACRIN approved your","type":"Preferred Question Text","description":"Has ECOG-ACRIN approved your access to, or ability to manufacture, the 18F-Fluorothymidine radiotracer required to perform the PET/CT scans?","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94542F86-4E30-74C4-E053-F662850A37FA","latestVersionIndicator":"Yes","beginDate":"2019-10-07","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2019-10-07","modifiedBy":"GARRIDOJ","dateModified":"2021-03-08","changeDescription":"Created for EA6183, 10/07/2019 JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}